Stock events for Beyond Air, Inc. (XAIR)
Over the past six months, Beyond Air's stock has declined significantly. Key events impacting the stock price include the Q3 Fiscal Year 2026 Earnings Report, CFO appointments, securing financing, and a significant stock price decline on January 14, 2026. In Q3, Beyond Air reported a 105% year-over-year increase in revenue, exceeding analyst expectations, but its GAAP EPS missed estimates. The company appointed Duke Drewell as interim CFO in November 2025, followed by Dan Moorhead as CFO in December 2025. Beyond Air secured $3.25 million via warrant exercise and a new issuance in December 2025. XTL Biopharmaceuticals agreed to acquire 85% of Beyond Air's subsidiary NeuroNOS in January 2026.
Demand Seasonality affecting Beyond Air, Inc.’s stock price
Demand seasonality for Beyond Air's products and services is primarily linked to the nature of the respiratory conditions it aims to treat. The U.S. pilot trial for LungFit PRO is designed to extend over two seasons, suggesting seasonal fluctuations in demand for treatments related to respiratory infections. For LungFit PH, the company anticipates continued sequential quarterly revenue growth driven by the expansion of its customer base. International revenue growth is projected to have a significant impact in the latter half of fiscal year 2026 and beyond.
Overview of Beyond Air, Inc.’s business
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company focused on developing innovative solutions for pulmonary and upper airway conditions, neurological disorders, and solid tumors, operating within the rapidly evolving medical device industry. The company's core mission is to leverage its proprietary LungFit™ system, a nitric oxide (NO) generator and delivery platform, to provide novel, non-invasive treatments, generating NO on demand from ambient air, eliminating the need for bulky gas cylinders. The company's major products and pipeline include LungFit PH, which is FDA approved and has a CE Mark in Europe for treating neonates with hypoxic respiratory failure associated with PPHN. LungFit PRO and LungFit GO are in clinical development for severe lung infections. Beyond Cancer, Ltd. is an affiliate focused on developing ultra-high concentration NO therapies for solid tumors. NeuroNOS is a program dedicated to neurological disorders.
XAIR’s Geographic footprint
Beyond Air, Inc. is headquartered in Garden City, New York. Its LungFit PH system is approved for commercial use in the United States, the European Union, and many other countries globally. The company has significantly expanded its international distribution network, which now covers 39 countries, including key markets such as Japan, Brazil, Mexico, Germany, Austria, the Netherlands, France, and Sri Lanka.
XAIR Corporate Image Assessment
Beyond Air's brand reputation has been influenced by positive developments and financial challenges. The company has received positive feedback regarding its LungFit PH system, and a review article highlighted the antimicrobial effects of high-dose inhaled nitric oxide. Beyond Air has also actively participated in healthcare investor conferences. However, the significant decline in its stock price and ongoing net losses could negatively affect investor confidence and public perception, and shareholders have experienced substantial dilution.
Ownership
Beyond Air, Inc. has a mix of institutional investors, company insiders, and the general public as owners. Major institutional owners include Alyeska Investment Group, L.P., Balyasny Asset Management L.P., and Geode Capital Management, Llc. Major individual insiders also hold a substantial portion of the company, with Lead Independent Director Robert Carey noted as one of the largest individual shareholders.
